Skip to content

Abliva

Delivering mitochondrial health

  • English
    • English
    • Svenska
  • Abliva
    • This is Abliva
      • Delivering mitochondrial health
      • Orphan Drugs
    • Relevant publications
  • Mitochondrial Disease
    • Primary mitochondrial disease
      • MELAS-MIDD and KSS-CPEO
      • Leigh Syndrome
      • LHON
    • Patients
    • Expanded access policy
  • Research & Development
    • Portfolio
      • KL1333
      • NV354
      • Early programs
    • Clinical trials
      • The FALCON Study
  • Contact
    • Privacy policy

Press releases

  • All
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
  • 2010
All MARRegulatory
21 February, 2025
Regulatory

Abliva AB Year-End Report January – December 2024

Positive Interim Analysis of the FALCON Study
Continue reading
29 November, 20249 December, 2024
Regulatory

Abliva AB Interim Report January – September 2024

- Positive Interim Analysis of the FALCON Study Paves the Way for KL1333 Development -
Continue reading
22 August, 20249 December, 2024
Regulatory

Abliva AB Interim Report January – June 2024

FALCON Positioned for Success Following Analysis by Independent Committee ⎮ Strong Safety Profile Confirmed, and Both Primary Endpoints Passed Futility
Continue reading
23 May, 2024
Regulatory

Abliva AB Interim Report January – March 2024

SEK 46 million raised through preferential rights issue | Preparations for the interim analysis ongoing
Continue reading
23 February, 2024
Regulatory

Abliva AB Year-End Report January – December 2023

40 Patients Enrolled in Wave 1 of the FALCON Study | Fast Track Designation for KL1333 | Orphan Drug Designation for NV354 in both US and Europe
Continue reading
17 November, 202319 February, 2024
Regulatory

Abliva AB Interim Report January – September 2023

KL1333 Received FDA Fast Track Designation | The FALCON Study Reached an Important Milestone
Continue reading
18 August, 2023
Regulatory

Abliva AB Interim Report January – June 2023

The first patient was dosed in the FALCON study ⎮ Orphan Drug Designation for NV354
Continue reading
23 May, 2023
Regulatory

Abliva AB Interim Report January – March 2023

Patient screening ongoing in the FALCON study | Orphan Drug Designation for NV354
Continue reading
24 February, 2023
Regulatory

Abliva AB Year-End Report January – December 2022

A successful financing enabled the start of the FALCON study with KL1333
Continue reading
22 November, 2022
Regulatory

Abliva AB Interim Report January – September 2022

Additional regulatory approvals to start the FALCON study with KL1333 ⎮ World Mitochondrial Disease Week raised awareness of mitochondrial diseases
Continue reading
19 August, 2022
Regulatory

Abliva AB Interim Report January – June 2022

SEK 200 million financing secured ⎮ KL1333 study due to start this year ⎮ NV354 is being prepared for clinical studies
Continue reading
31 May, 2022
Regulatory

Abliva AB Interim Report January – March 2022

First quarter summary
Continue reading

Posts navigation

Older posts
  1. Startpage

This is Abliva

  • Delivering mitochondrial health
  • Orphan Drugs
  • Relevant publications

Research & Development

  • Research & Development
  • KL1333
  • NV354
  • Early programs
  • The FALCON Study

Contact

Abliva AB (publ)
Medicon Village
223 81 Lund, Sweden

Phone
+46 (0)46-275 62 20

Generel questions
info@abliva.com

© Copyright 2020 – Abliva AB. All rights reserved. | We use cookies to improve our services | Cookie policy | Privacy policy

Cookies
We serve cookies. If you think that's ok, just click "Accept all". You can also choose what kind of cookies you want by clicking "Settings". Read our cookie policy
Settings Accept all
Cookies
Choose what kind of cookies to accept. Your choice will be saved for one year. Read our cookie policy
  • Necessary
    These cookies are not optional. They are needed for the website to function.
  • Statistics
    In order for us to improve the website's functionality and structure, based on how the website is used.
  • Experience
    In order for our website to perform as well as possible during your visit. If you refuse these cookies, some functionality will disappear from the website.
  • Marketing
    By sharing your interests and behavior as you visit our site, you increase the chance of seeing personalized content and offers.
Save Accept all